Impact of taxanes on androgen receptor signaling.

Shanshan Bai; Bryan Y Zhang; Yan Dong

Return

Impact of taxanes on androgen receptor signaling.

Author: Shanshan BAI ¹ ; Bryan Y ZHANG ² ; Yan DONG ³
Author Information

1. College of Life Sciences, Jilin University, Changchun 130012, China.
2. Lusher Charter School, New Orleans, LA 70115, USA.
3. Department of Structural and Cellular Biology, Tulane University School of Medicine, Tulane Cancer Center, New Orleans, LA 70112, USA.
Publication Type:Review
Keywords: androgen receptor; androgen receptor splice variant; cabazitaxel; docetaxel; prostate cancer; taxane
MeSH: Antineoplastic Agents, Phytogenic/therapeutic use*; Humans; Male; Prostatic Neoplasms, Castration-Resistant/drug therapy*; Receptors, Androgen/drug effects*; Signal Transduction/drug effects*; Taxoids/therapeutic use*
From: Asian Journal of Andrology 2019;21(3):249-252
CountryChina
Language:English
Abstract: The development and progression of metastatic castration-resistant prostate cancer is the major challenge in the treatment of advanced prostate cancer. The androgen receptor signaling pathway remains active in metastatic castration-resistant prostate cancer. Docetaxel and cabazitaxel are the first- and second-line chemotherapy, respectively, for patients with metastatic castration-resistant prostate cancer. These two taxanes, in general, function by (i) inhibiting mitosis and inducing apoptosis and (ii) preventing microtubule-dependent cargo trafficking. In prostate cancer, taxanes have been reported to inhibit the nuclear translocation and activity of the androgen receptor. However, whether this is attainable or not clinically remains controversial. In this review, we will provide a comprehensive view of the effects of taxanes on androgen receptor signaling in prostate cancer.